trial

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

NCTId NCT00781755
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by VA Boston Healthcare System
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
—
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
VareniclineAdaptation of Motivational Interviewing

Sponsors

VA Boston Healthcare SystemLead Sponsor

Investigators

4
Professor Gary Donohoe, Ph.D.Principal Investigator
Suzy Bird Gulliver, Ph.D.Study Chair
Barbara D'Avanzo, Phil.D.Study Chair
James Levitt, M.D.Study Chair

Sites

1 total
Brockton, United States

Facts & assertions

3 sourced
Enrollment
0
Phase
PHASE4
Status
WITHDRAWN
relationships
The graph out of here
drug
Varenicline
drug
Adaptation of Motivational Interviewing
drug
lead_sponsor
VA Boston Healthcare System
company
indication
Smoking
indication
Tobacco Use Disorder
indication
Schizophrenia
indication
investigator
Professor Gary Donohoe, Ph.D.
person
Suzy Bird Gulliver, Ph.D.
person
Barbara D'Avanzo, Phil.D.
person
James Levitt, M.D.
person